GlassScriptPhysician profile
Gauri G Kanhere
NPI 1710910773
$2,143.12
in general payments reported to CMS, 2019-2025
23 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $311 · 2021: $349 · 2022: $308 · 2023: $541 · 2024: $291 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $325.75 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $309.58 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $245.88 | 2021-2025 | |
| Astellas Pharma US INC | $229.69 | 2019-2022 | |
| Lilly USA, LLC | $148.43 | 2020-2024 | Jardiance, Emgality, Trulicity |
| Janssen Pharmaceuticals, INC | $133.63 | 2023 | Xarelto |
| Novo Nordisk INC | $113.85 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $109.36 | 2019-2024 | Prolia, Evenity, Repatha |
| Allergan, INC. | $96.91 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.61 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $60.19 | 2020-2024 | Verquvo, Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $47.60 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.48 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $32.16 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $28.56 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $27.59 | 2020-2025 | Nexletol |
| Exact Sciences Corporation | $23.42 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $21.32 | 2025 | Freestyle Libre 3 |
| Phadia US INC. | $19.93 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.57 | 2024 | |
| Sumitomo Pharma America, INC. | $17.04 | 2024 | Gemtesa |
| Biogen, INC. | $13.02 | 2021 | |
| Insulet Corporation | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gauri Kanhere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.